February 2025's Global Undervalued Small Caps With Insider Buying

In February 2025, global markets are navigating a landscape marked by geopolitical tensions and consumer spending concerns, with major indices experiencing volatility due to tariff fears and economic uncertainty. Despite these challenges, small-cap stocks continue to present unique opportunities for investors seeking growth potential amid fluctuating market conditions. Identifying promising small-cap stocks often involves looking for companies with strong fundamentals and insider buying activity, which can indicate confidence in the company's future prospects even in uncertain times.

Top 10 Undervalued Small Caps With Insider Buying Globally

Name	PE	PS	Discount to Fair Value	Value Rating
Bytes Technology Group	20.4x	5.2x	20.47%	★★★★★★
4imprint Group	17.4x	1.4x	30.75%	★★★★★☆
Speedy Hire	NA	0.2x	25.88%	★★★★★☆
Gamma Communications	22.7x	2.3x	34.98%	★★★★☆☆
ABG Sundal Collier Holding	12.2x	1.9x	20.33%	★★★★☆☆
CVS Group	29.0x	1.2x	38.03%	★★★★☆☆
Franchise Brands	39.2x	2.0x	24.96%	★★★★☆☆
JiaXing Gas Group	5.8x	0.3x	49.59%	★★★★☆☆
Optima Health	NA	1.5x	45.28%	★★★★☆☆
Logistri Fastighets	17.3x	8.2x	17.07%	★★★☆☆☆

Click here to see the full list of 108 stocks from our Undervalued Global Small Caps With Insider Buying screener.

Underneath we present a selection of stocks filtered out by our screen.

IPD Group (ASX:IPG)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: IPD Group operates in the electrical equipment industry, focusing on the distribution of a wide range of products and services, with a market cap of A$0.36 billion.

Operations: IPD Group generates revenue primarily from its Products Division, contributing significantly more than the Services Division. The company's gross profit margin has shown variation, peaking at 39.43% and declining to 35.15% over recent periods. Operating expenses are a notable cost factor, with General & Administrative Expenses being the largest component within this category.

PE: 17.0x

IPD Group, a smaller company in its industry, recently demonstrated insider confidence with Mohamed Yoosuff acquiring 1 million shares for A$3.78 million, reflecting a 9.68% change in their holdings. For the half-year ending December 31, 2024, sales surged to A$176.94 million from A$120.74 million the previous year, while net income rose to A$13.35 million from A$9.55 million. Despite relying on external borrowing for funding, IPD's earnings are projected to grow by approximately 11% annually, indicating potential growth opportunities ahead.

• Get an in-depth perspective on IPD Group's performance by reading our valuation report here.

• Review our historical performance report to gain insights into IPD Group's's past performance.

Nyab (OM:NYAB)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Nyab is a company engaged in heavy construction operations, with a market capitalization of approximately €314.33 million.

Operations: The company generates revenue primarily from heavy construction, with recent quarterly revenues reaching €314.33 million. Over the observed periods, the gross profit margin shows fluctuations, peaking at 26.76% and recently recorded at 22.66%. Operating expenses are a significant cost factor, consistently impacting net income margins across various quarters.

PE: 30.2x

Nyab's recent financials reveal a promising trajectory, with sales climbing to €345.94 million and net income reaching €16.75 million in 2024. Despite lower profit margins at 3.5%, the company has captured significant contracts, including a €13-17 million tramway project in Uppsala and a SEK 132 million pipeline construction for Trosa municipality. Insider confidence is evident as executives increase their holdings, suggesting belief in future growth prospects despite reliance on external borrowing for funding.

• Click here to discover the nuances of Nyab with our detailed analytical valuation report.

• Explore historical data to track Nyab's performance over time in our Past section.

Raffles Medical Group (SGX:BSL)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Raffles Medical Group operates in hospital services, insurance services, healthcare services, and investment holdings with a market cap of approximately SGD 2.09 billion.

Operations: Raffles Medical Group generates revenue primarily from hospital, insurance, and healthcare services. The company reported a gross profit margin of 55.07% as of June 2023, reflecting its ability to manage costs relative to revenue. Operating expenses have been significant, contributing to variations in net income margins over time.

PE: 27.5x

Raffles Medical Group, a smaller player in the healthcare sector, has shown insider confidence with Executive Chairman & CEO Choon Yong Loo purchasing 1.7 million shares for approximately S$1.5 million, indicating belief in the company's potential despite recent challenges. The firm reported a drop in net income to S$62.24 million for 2024 from S$90.15 million the previous year, although sales increased to S$751.56 million from S$706.92 million. Recent leadership changes and dividend increases suggest strategic positioning for future growth within its competitive landscape.

• Dive into the specifics of Raffles Medical Group here with our thorough valuation report.

• Gain insights into Raffles Medical Group's historical performance by reviewing our past performance report.

Key Takeaways

• Discover the full array of 108 Undervalued Global Small Caps With Insider Buying right here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com